Chemoimmunotherapy dramatically improved survival of high-risk neuroblastoma patients



Chemoimmunotherapy dramatically improved survival of high-risk neuroblastoma patients

A recent phase II clinical trial results suggest that the monoclonal antibody hu14.18K322A could help change treatment of children with high-risk neuroblastoma.

Materials provided by St. Jude Children’s Research Hospital. Note: Content may be edited for style and length.




Source link aaaaa

Related posts

9th December 2022

Clues found regarding tumor suppressor gene's breast cancer activity

Read more
9th December 2022

New findings on how to avert excessive weight loss from COVID-19

Read more
9th December 2022

P53 could be key to therapies for salivary gland cancer

Read more